Thore Hettmann

4.4k total citations · 1 hit paper
22 papers, 3.5k citations indexed

About

Thore Hettmann is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Thore Hettmann has authored 22 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Immunology. Recurrent topics in Thore Hettmann's work include HER2/EGFR in Cancer Research (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Immune Cell Function and Interaction (5 papers). Thore Hettmann is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Immune Cell Function and Interaction (5 papers). Thore Hettmann collaborates with scholars based in United States, Germany and Canada. Thore Hettmann's co-authors include Jeffrey M. Leiden, Chi Young Yun, Yuhong Zhang, John C. Bell, Heather P. Harding, Navid Sadri, Phoebe D. Lu, Brian Popko, Isabel Novoa and David F. Stojdl and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Thore Hettmann

22 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Integrated Stress Response Regulates Amino Acid Metabolism and Resistance to Oxidative Stress

2003 2.6k citations Heather P. Harding, Yuhong Zhang et al. Molecular Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thore Hettmann United States	14	2.0k	1.7k	724	488	367	22	3.5k
Navid Sadri United States	17	2.2k 1.1×	1.6k 1.0×	745 1.0×	368 0.8×	539 1.5×	43	3.8k
Donna J. Thuerauf United States	34	2.5k 1.2×	1.9k 1.1×	986 1.4×	365 0.7×	258 0.7×	47	4.2k
Clark Distelhorst United States	43	3.8k 1.9×	1.1k 0.7×	835 1.2×	759 1.6×	469 1.3×	82	5.3k
Michael S. Kilberg United States	31	2.9k 1.4×	2.0k 1.2×	778 1.1×	343 0.7×	402 1.1×	46	4.8k
Kei Tobiume Japan	22	3.2k 1.6×	1.2k 0.7×	684 0.9×	689 1.4×	804 2.2×	45	4.6k
Diego Acosta‐Alvear United States	20	2.1k 1.0×	1.8k 1.1×	922 1.3×	348 0.7×	164 0.4×	29	3.4k
Katiuscia Bianchi United Kingdom	17	2.7k 1.3×	871 0.5×	1.2k 1.6×	586 1.2×	344 0.9×	27	4.1k
Jaeseok Han South Korea	28	2.0k 1.0×	2.2k 1.3×	1.3k 1.8×	479 1.0×	234 0.6×	57	4.4k
Junichi Hitomi Japan	15	3.1k 1.5×	1.4k 0.8×	1.1k 1.5×	1.1k 2.2×	450 1.2×	17	4.6k
Catherine H. Liu United States	23	4.4k 2.1×	1.6k 0.9×	237 0.3×	832 1.7×	455 1.2×	25	6.1k

Countries citing papers authored by Thore Hettmann

Since Specialization

Citations

This map shows the geographic impact of Thore Hettmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thore Hettmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thore Hettmann more than expected).

Fields of papers citing papers by Thore Hettmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thore Hettmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thore Hettmann. The network helps show where Thore Hettmann may publish in the future.

Co-authorship network of co-authors of Thore Hettmann

This figure shows the co-authorship network connecting the top 25 collaborators of Thore Hettmann. A scholar is included among the top collaborators of Thore Hettmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thore Hettmann. Thore Hettmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Tao, Qiaoqiao Shi, Yongzhi Zhang, et al.. (2021). Focused ultrasound with anti-pGlu3 Aβ enhances efficacy in Alzheimer's disease-like mice via recruitment of peripheral immune cells. Journal of Controlled Release. 336. 443–456. 30 indexed citations

Bathini, Praveen, Tao Sun, Qiaoqiao Shi, et al.. (2021). Focus Ultrasound‐Induced Blood‐Brain Barrier opening enhances anti‐pGlu3 Aβ mAb delivery and amyloid‐beta plaque clearance. Alzheimer s & Dementia. 17(S2). 1 indexed citations

Hettmann, Thore, Stephen D. Gillies, Martin Kleinschmidt, et al.. (2020). Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation. Scientific Reports. 10(1). 3294–3294. 22 indexed citations

Crehan, Helen, Bin Liu, Martin Kleinschmidt, et al.. (2020). Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice. Alzheimer s Research & Therapy. 12(1). 12–12. 28 indexed citations

Mendell, Jeanne, Daniel J. Freeman, Wenqin Feng, et al.. (2015). Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer. EBioMedicine. 2(3). 264–271. 30 indexed citations

Desmet, Johan, Kenneth Verstraete, Yehudi Bloch, et al.. (2014). Structural basis of IL-23 antagonism by an Alphabody protein scaffold. Nature Communications. 5(1). 5237–5237. 53 indexed citations

LoRusso, Patricia, Pasi A. Jänne, Moacyr Oliveira, et al.. (2013). Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(11). 3078–3087. 74 indexed citations

Pfeil, Ines, et al.. (2012). Abstract 2519: U3-1565, a fully human anti-HB-EGF monoclonal antibody, inhibits oncogenic signaling and tumor cell growth in vitro and in vivo. Cancer Research. 72(8_Supplement). 2519–2519. 2 indexed citations

Gillies, Stephen D., Yan Lan, Thore Hettmann, et al.. (2011). A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity. Clinical Cancer Research. 17(11). 3673–3685. 77 indexed citations

10.

Keedy, Vicki L., Pasi A. Jänne, Lorrin Yee, et al.. (2011). A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3026–3026. 7 indexed citations

11.

Freeman, Daniel J., et al.. (2011). Abstract A182: U3–1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in the FaDu model of human squamous cell carcinoma of the head and neck (SCCHN).. Molecular Cancer Therapeutics. 10(11_Supplement). A182–A182. 13 indexed citations

12.

Treder, Martin, et al.. (2008). 309 POSTER Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models. European Journal of Cancer Supplements. 6(12). 99–99. 15 indexed citations

13.

Harding, Heather P., Yuhong Zhang, Isabel Novoa, et al.. (2003). An Integrated Stress Response Regulates Amino Acid Metabolism and Resistance to Oxidative Stress. Molecular Cell. 11(3). 619–633. 2607 indexed citations breakdown →

14.

Hettmann, Thore. (2003). A critical role for NF-κB transcription factors in the development of CD8+ memory-phenotype T cells. Immunology Letters. 85(3). 297–300. 20 indexed citations

15.

Hettmann, Thore & Jeffrey M. Leiden. (2000). NF-κB Is Required for the Positive Selection of CD8+ Thymocytes. The Journal of Immunology. 165(9). 5004–5010. 55 indexed citations

16.

Hettmann, Thore, Kevin Barton, & Jeffrey M. Leiden. (2000). Microphthalmia due to p53-mediated apoptosis of anterior lens epithelial cells in mice lacking the CREB-2 transcription factor. Developmental Biology. 222(1). 110–123. 117 indexed citations

17.

Hettmann, Thore, Joseph A. DiDonato, Michael Karin, & Jeffrey M. Leiden. (1999). An Essential Role for Nuclear Factor κB in Promoting Double Positive Thymocyte Apoptosis. The Journal of Experimental Medicine. 189(1). 145–158. 188 indexed citations

18.

Hettmann, Thore & Amos Cohen. (1995). Identification of an ionomycin/cyclosporin A‐responsive element within the human T cell receptor gamma enhancer. European Journal of Immunology. 25(12). 3356–3364. 3 indexed citations

19.

Hettmann, Thore & Amos Cohen. (1994). Identification of a T cell-specific transcriptional enhancer 3′ of the human T cell receptor gamma locus. Molecular Immunology. 31(4). 315–322. 8 indexed citations

20.

Hettmann, Thore, Paul J. Doherty, & Amos Cohen. (1992). The human T cell receptor gamma genes are transcribed from tata-less promoters containing a conserved heptamer sequence. Molecular Immunology. 29(9). 1073–1080. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact